Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus BENSULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus BENSULFOID.
BACTROBAN vs BENSULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Bensulfoid: not a recognized drug. No data available.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Category C
Category C
Topical Antibiotic
Topical Antibiotic